Press Release
This document provides integrated information to the media. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
-
Management & FinanceFY2025 Results Briefing Session - Material
-
Management & FinanceFY2025 Full Year Financial Report
-
Management & FinanceNotice Concerning Partial Corrections to the Annual Securities Report for Past Fiscal Years and the Consolidated Financial Results for the Nine Months Ended December 31, 2025 (FY2025) and Other Relevant Documents
-
Research & DevelopmentJCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
-
Management & FinanceRevision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2026
-
CompanyNotice of Election of Candidate for New Outside Director
-
CompanyNotice of Personnel Change
-
Research & DevelopmentJCR Pharmaceuticals Initiates Phase III Dose Comparison Study of GROWJECT™ S.C. Injection 12mg in Japan
-
CompanyJCR Pharmaceuticals Launches Redesigned Corporate Website
-
CompanyAnnouncement of Executive Appointments and Organizational Changes